Skip to Content

Generic Karbinal ER Availability

Karbinal ER is a brand name of carbinoxamine, approved by the FDA in the following formulation(s):

KARBINAL ER (carbinoxamine maleate - suspension, extended release;oral)

  • Manufacturer: TRIS PHARMA INC
    Approval date: March 28, 2013
    Strength(s): 4MG/5ML [RLD]

Has a generic version of Karbinal ER been approved?

No. There is currently no therapeutically equivalent version of Karbinal ER available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Karbinal ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modified release formulations containing drug-ion exchange resin complexes
    Patent 8,062,667
    Issued: November 22, 2011
    Inventor(s): Mehta; Ketan & Tu; Yu-Hsing
    Assignee(s): Tris Pharma, Inc.
    A coated drug-ion exchange resin complex comprising a core composed of a drug complexed with a pharmaceutically acceptable ion-exchange resin is provided. The drug-ion exchange resin complex is in admixture with a release retardant. The coating is a polyvinyl acetate polymer and a plasticizer. Methods of making and products containing this coated complex are described.
    Patent expiration dates:
    • March 29, 2029
      Drug product


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.